We have advised Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, on its $88 million Series D financing.
Temasek led the round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital and Sequoia.
Cambridge Epigenetix is revolutionising sequencing by delivering new dimensions of information from DNA to see and treat disease earlier. The company’s platform provides more information with greater efficiency at higher quality and lower cost than standard next generation DNA sequencing technology. Easily integrating into existing sequencers, the company’s products will allow the user to see at-a-glance genomic and epigenetic information which can be used to detect, diagnose, treat and understand disease.
Proceeds from the financing will be used to commercialise the company’s proprietary genetic and epigenetic sequencing technology. The technology has been validated by leading genomic research institutions and several have continued using the technology through early access programs.
Commenting on the transaction, corporate partner Ross McNaughton said: "We are delighted to have helped Cambridge Epigenetix with this landmark transaction, adding Temasek to its existing list of industry leading investors. The company is developing some leading-edge technology in the areas of genetics and epigenetics and is another example of the strength of innovation emanating from within the Cambridge ecosystem."
Executive Chair of Cambridge Epigenetix, Gail Marcus, added: "We are delighted to have secured this financing to support the commercial launch of CEGX's products, which will make significant contributions to DNA sequencing, epigenomic research and precision medicine. We would like to thank Ross and Oli and the rest of the Taylor Wessing team for delivering an outstanding service, demonstrating their deep knowledge of the tech and life sciences sectors."
The transaction was led by partner Ross McNaughton with support from associate Oli Denne.
